(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.41%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.85%.
Alx Oncology Holdings's earnings in 2026 is -$88,868,000.On average, 8 Wall Street analysts forecast ALXO's earnings for 2026 to be -$82,904,213, with the lowest ALXO earnings forecast at -$94,947,594, and the highest ALXO earnings forecast at -$72,058,442. On average, 8 Wall Street analysts forecast ALXO's earnings for 2027 to be -$81,800,797, with the lowest ALXO earnings forecast at -$98,903,744, and the highest ALXO earnings forecast at -$60,755,157.
In 2028, ALXO is forecast to generate -$76,862,338 in earnings, with the lowest earnings forecast at -$105,497,327 and the highest earnings forecast at -$48,038,961.